Powder: -20°C for 3 years | In solvent: -80°C for 2 years
PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 116.00 | |
5 mg | In stock | $ 289.00 | |
10 mg | In stock | $ 497.00 | |
25 mg | In stock | $ 793.00 | |
50 mg | In stock | $ 1,130.00 | |
100 mg | In stock | $ 1,520.00 | |
500 mg | In stock | $ 2,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 318.00 |
Description | PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer. |
Targets&IC50 | transforming growth factor-beta receptor 1: |
In vivo | In MCF-7 ER+ HER2-xenograft breast cancer tumor model, PF-06952229 (30 mg/kg; gavage) combines with Palbociclib results in an improved inhibition of pSMAD2 and a significant increase in survival[1]. |
Synonyms | PF06952229 |
Molecular Weight | 458.91 |
Formula | C23H24ClFN4O3 |
CAS No. | 1801333-55-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 40 mg/mL (87.2 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-06952229 1801333-55-0 Stem Cells TGF-beta/Smad PF06952229 inhibitor inhibit